232 results about "Eye drops solution" patented technology

The invention discloses a liquid chromatography detection method and system for eye drops, and relates to the technical field of chromatographic detection.The liquid chromatography detection method comprises the steps that liquid chromatography analysis is conducted to obtain an original chromatographic signal; performing adaptive baseline correction on the original chromatographic signal to obtain a corrected chromatographic signal, synchronizing the corrected chromatographic signal to a chromatographic peak identification analysis model for identification to obtain a plurality of chromatographic peaks including principal component peaks and specific impurity peaks, and performing calculation to obtain a first integral area of the principal component peaks and a second integral area of the specific impurity peaks; the preset correction factor is combined with the first integral area and the second integral area to automatically carry out quantitative calculation on the eye drops, and a liquid chromatogram detection report of the eye drops is generated. The technical problems that in the prior art, main component peak and impurity peak recognition and quantification depend on manual processing in the eye drop liquid chromatogram detection process, and accuracy and consistency are insufficient are solved, and the technical effects that the accuracy and automation level of eye drop liquid chromatogram detection are improved, and it is guaranteed that main component and impurity quantification results are stable and consistent are achieved.

The invention relates to a near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system and a preparation method and application thereof, a mesoporous silicon coated up-conversion nano-carrier and an efficient photosensitizer are compounded to form a photo-response core unit, and then the photo-response core unit is intelligently integrated with photo-curing hydrogel to form the near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system. The general problem of aggregation and quenching of photosensitive molecules is relieved by utilizing the unique space confinement effect of the mesoporous structure, the ICG photo-thermal efficiency and photodynamic performance are enhanced, under precise excitation of a near-infrared light source, the system can activate a photo-crosslinking reaction through an up-conversion luminescence process, in-situ conversion from a liquid eye drop preparation to a stable gel state is achieved, and the stability of the eye drop preparation is improved. A lasting drug reservoir is formed on the surface of the cornea; synchronously excited photodynamic and photo-thermal dual-mode treatment generates a remarkable synergistic antibacterial effect, and shows an excellent removal capability on pathogens including highly drug-resistant bacteria; meanwhile, an ideal microenvironment is created for tissue repair through high biocompatibility and a stable mechanical matrix, and integrity recovery of cornea structures and functions is promoted.

The invention discloses traditional Chinese medicine suspension eye drops and a preparation method thereof, and the traditional Chinese medicine suspension eye drops are prepared from the following raw materials in parts by weight: 1-3 parts of a traditional Chinese medicine composition, 4-7 parts of hydroxypropyl-beta-cyclodextrin, 0.5-2 parts of microcrystalline cellulose-sodium carboxymethyl cellulose and auxiliary materials. The traditional Chinese medicine suspension eye drops provided by the invention abandon a traditional eye ointment form, are directly dropped for use, are convenient to use, have good stability and dispersity, and are excellent in use curative effect and medication experience; on the basis of keeping the clinical efficacy of the Marcher eight-treasure ancient prescription, secondary development and research are scientifically carried out, so that the Marcher eight-treasure ancient prescription plays a greater clinical treatment role, and has a wider market development prospect.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

The invention discloses a composition and a preparation method of a single-dose vitamin B12 eye drop without a bacteriostatic agent, and the single-dose vitamin B12 eye drop without the bacteriostatic agent is prepared from vitamin B12, a buffering agent, sodium hyaluronate, edetate disodium and water for injection. According to the vitamin B12 eye drops and the preparation method thereof disclosed by the invention, the vitamin B12 eye drops are produced by adopting a totally-closed sterile filling process, and a disposable single-dose packaging container is arranged, so that the sterility of medicines is ensured, and meanwhile, the use safety, the operation convenience index and the safety performance are improved.

The invention discloses a self-emulsifying nervonic acid eye drop, which is prepared from the following raw material components in percentage by mass: 1 to 10 weight percent of nervonic acid, 30 to 60 weight percent of oil phase, 20 to 40 weight percent of surfactant and 10 to 20 weight percent of co-emulsifier, the oil phase is at least one of sunflower seed oil, squalane, olive oil and castor oil. According to the invention, the oil phase rich in unsaturated fatty acid is adopted, so that the eye cream has good solubility to nervonic acid, is mild and low-sensitive, can soften the cuticle of eyes and reduce the permeation resistance of nervonic acid, and is suitable for sensitive periocular skin. The prepared self-emulsifying nervonic acid eye drops overcome the defect that nervonic acid is almost insoluble in water, and compared with water-based eye drops, the self-emulsifying nervonic acid eye drops have the advantage that the drug loading capacity and the stability are obviously improved.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses timolol maleate eye drops and a preparation method thereof. The timolol maleate eye drops provided by the invention are prepared from timolol maleate, glycine, trehalose, disodium hydrogen phosphate and sodium dihydrogen phosphate. According to the timolol maleate eye drops, the components of the timolol maleate eye drops are reasonably designed, and glycine and trehalose are added into the timolol maleate eye drops, so that degradation of active components of the timolol maleate eye drops is also reduced while the types and the dosage of auxiliary materials are reduced, and the eye drops have the advantages that the eye drops are safe and reliable; the stability of the timolol maleate eye drops placed for a long time is obviously improved, and the medication safety of the timolol maleate eye drops is ensured.

1. Name of the designed product: packing box (sodium hyaluronate eye drops). 2. Use of the designed product: the designed product is mainly used for packing of medicines. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: design 1 perspective view. 5. Design 1 is designated as the basic design.

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The invention relates to a single-dose pilocarpine hydrochloride eye drop composition and a preparation method thereof, and belongs to the technical field of medicine preparation. The composition comprises a buffering agent, an osmotic pressure regulator and a solvent, and the composition does not contain a bacteriostatic agent. By using reasonable process preparation parameters, the prepared finished product is good in stability, the process parameters are simple and easy to operate, and the method has good application prospects and market value.

The utility model discloses eye drop medicine bottle cleaning equipment which comprises a mounting plate, a power source arranged near the mounting plate, a pushing piece connected with the power source, a pushing plate arranged on the mounting plate in a sliding mode, a clamping piece arranged below the pushing plate and a containing opening formed in the pushing plate. The liquid medicine bottle is placed in the placing opening, and the water spraying holes are formed in the mounting plate; the liquid medicine bottle is fixed in the containing opening through the clamping piece, the power source pushes the pushing plate through the pushing piece, and the liquid medicine bottle is moved to the water spraying hole to be cleaned. According to the eye drop medicine bottle cleaning equipment, batch cleaning of medicine bottles is achieved, the production efficiency is improved, the cleaning effect is ensured, and the pollution risk caused by manual intervention is reduced.

The invention discloses difunctional nano drug-loaded eye drops for xerophthalmia and a preparation method of the difunctional nano drug-loaded eye drops, and belongs to the field of pharmaceutical preparation technologies and ophthalmology pharmacy. The core of the invention is to construct a composite nanoparticle which has a core-shell structure and has long-acting adhesion lubrication and targeted control drug release functions. The preparation method comprises the following steps: firstly, encapsulating a hydrophobic immunosuppressant such as cyclosporine A in a biodegradable pad polymer matrix such as polylactic acid-glycolic acid copolymer (PLGA) by an emulsification-solvent evaporation method to form a drug-loaded polymer nano core; through the exquisite integrated design of the structure and the function, collaborative targeted therapy of two core pathological links of'tear film instability 'and'immune inflammation' of xerophthalmia is achieved, the bioavailability of the medicine is remarkably improved, the medication frequency and eye irritation are reduced, and the curative effect of xerophthalmia is improved. A more efficient and safer administration scheme with better patient compliance is provided for clinical treatment of xerophthalmia.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The present application relates to the technical field of medicine, in particular to a kind of siRNA eye drop for penetrating mucus barrier and cell barrier and preparation method thereof.Innovative development side chain guanidino group-containing polydisulfide delivery carrier is used in the present application, through the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on mucin, tear film retention and efficient penetration are realized, and cationic polydisulfide is quickly adsorbed on the surface of negative charged cell membrane by electrostatic interaction, the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on cell membrane is used, and endocytosis is used to quickly penetrate tight junction cell layer.

The application discloses an eye preparation composition for treating presbyopia with longer action time and fewer adverse reactions and a preparation method thereof. The composition contains pilocarpine with a mass volume percentage of 0.42-1.02% (equivalent to 0.50-1.20% of hydrochloric acid pilocarpine and 0.55-1.33% of nitric acid pilocarpine), sodium carboxymethylcellulose with a mass percentage of 0.03-0.3%, hydroxyethyl p-henyl-ethyl ester with a mass percentage of 0.03-0.06%, and sodium chloride with a mass percentage of 0.6-0.8%. The prepared pilocarpine eye drops have the advantages of effectively enhancing the corneal permeability of pilocarpine, prolonging the retention time of the eye drops in eyes, reducing the use frequency while improving the pilocarpine miosis effect and treating presbyopia, reducing the irritation and damage of pilocarpine to corneas, and reducing the incidence of systemic adverse reactions compared with the related preparations on the market. In addition, the prescription pH value of the application is 4.0-5.0, which can effectively reduce the generation of impurities such as pilocarpine acid and ensure the product quality in the whole life cycle.

The utility model discloses a pranoprofen eye drop quantitative filling device, which relates to the technical field of eye drop filling, and comprises a filling pipe and a quantitative component, the lower end of the filling pipe is connected with a quantitative pipe, the front side of the quantitative pipe is provided with an observation window, the quantitative component for quantitative filling is arranged in the quantitative pipe, and the observation window is arranged on the front side of the quantitative pipe. And the quantitative assembly comprises an inner mounting frame, a protection pipe, a hydraulic rod, a top partition plate, a connecting rod and a bottom partition plate, the protection pipe is installed in the middle of the lower end of the inner mounting frame, the hydraulic rod is arranged in the protection pipe, and the output end of the hydraulic rod is connected with the top partition plate. According to the quantitative filling device for the pranoprofen eye drops, the inner sides of the top partition plate and the bottom partition plate play a quantitative liquid separation role on the eye drops, when the bottom partition plate further moves downwards to exceed the bottom of the quantitative tube, the quantitative eye drops are filled through the filling head, and at the moment, the top partition plate plays a separation role on the eye drops in the liquid storage box in the quantitative tube; the eye drops are prevented from being polluted.

1. Name of the product in this design: Packaging Box (Taurine Eye Drops). 2. Purpose of this design: For packaging eye drops. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

1.The name of the design product: packaging box (compound bear gall eye drop 1). 2.The use of the design product: for packaging products. 3.The design points of the design product: the combination of patterns and colors. 4.The picture or photo that best shows the design points: front view. 5.The design contains colors.

The utility model relates to a raw material medicine centrifugal device, which belongs to the technical field of eye drop raw material production, and comprises a machine body shell, a rotary drum outer cylinder, a support frame, a sealing cover, a movable seat, a rotary drum, a rotary shaft, a rotary disc, a liquid discharge filter part, a liquid accumulation cover, an electric push rod, an annular groove and a telescopic rod. According to the bulk drug centrifugal device, when a tropicamide material is centrifuged, the rotary drum on the rotary shaft rotates, the rotary disc is synchronously driven to be attached to and seal the inner wall of the rotary drum outer barrel to rotate, so that a solid material is deposited in the rotary drum outer barrel, liquid is separated into the liquid accumulation cover, and when the separated liquid is discharged, the liquid is discharged through the liquid discharging filter part on the rotary disc; and meanwhile, the solid materials are filtered and isolated into the rotary drum outer barrel, so that after centrifugation is completed, the electric push rod is started to work to push the sealing cover to be separated from the rotary drum outer barrel, the telescopic rod stretches to push the rotary disc to move downwards, the separated solid materials in the rotary drum outer barrel can be automatically discharged, and batch centrifugation work is achieved.

The invention belongs to the technical field of eye care, and provides vitamin B12-containing contact lens lubricating eye drops and a preparation method thereof, and the vitamin B12-containing contact lens lubricating eye drops comprise 0.5 to 0.7 part of sodium hyaluronate, 0.18 to 0.23 part of a tackifier, 0.3 to 0.35 part of polyvinyl alcohol, 1.1 to 1.2 parts of soybean phospholipid, 0.2 to 0.3 part of sodium cromoglycate, 0.7 to 0.9 part of vitamin B12, 0.005 to 0.01 part of borneol, 0.1 to 0.15 part of a surfactant, 0.1 to 0.18 part of a sodium chloride solution, 0.3 to 0.4 part of tiloxamer and 80 to 90 parts of water. The sodium hyaluronate and the polyvinyl alcohol have moisturizing and thickening effects, the sodium cromoglycate can effectively diminish inflammation and kill viruses, and conjunctivitis and other eye diseases are avoided; vitamin B12 can moisten corneas and relieve eye fatigue. Through cooperative use of the raw materials, the effects of moistening eyes, diminishing inflammation and relieving are achieved.

This invention relates to a sustained-release eye drop and its preparation method, belonging to the field of ophthalmic drug technology. The invention provides a self-assembled microparticle comprising an elastin-like peptide and sodium hyaluronate; the molar ratio of the elastin-like peptide to sodium hyaluronate is 5-7:1-2; the amino acid sequence of the elastin-like peptide is shown in SEQ ID NO.1. The self-assembled microparticles of this invention have a sustained-release effect and exhibit synergistic properties with hydroxypropyl methylcellulose. The eye drops prepared by combining these two components possess excellent sustained-release performance, adhesion, and stability, allowing for prolonged application to the eye, effectively solving the problem of short duration of action in existing eye drops.

The utility model discloses filling equipment for eye drop production, which relates to the technical field of eye drop filling equipment and comprises a conveying table, a support frame is fixedly connected to the rear side of the conveying table, a liquid storage tank is fixedly connected to the front side of the top end of the support frame, and a filling mechanism is fixedly connected to the bottom end of the liquid storage tank. The top end of the conveying table is rotationally connected with a feeding disc, and a guide plate is fixedly mounted on the left side of the top of the conveying table. When the eye drops are filled, the eye drops can enter the liquid storage tank at the top through the connecting pipe, the rotating disc can drive the liquid storage tank to rotate by starting the first motor, so that the eye drops in the liquid storage tank can be discharged from the liquid discharge pipe, the operation is simple, continuous filling of the eye drops is realized, and the filling efficiency of the eye drops is improved. And meanwhile, by adjusting the size of the liquid storage tank, the filling amount of each time can be accurately controlled, and the eye drop filling equipment is convenient to use.

The invention relates to eye drops containing umbilical cord mesenchymal stem cell exosomes. The eye drops are prepared from the following raw materials: sodium hyaluronate, an L-ascorbyl palmitate / hydroxypropyl-beta-cyclodextrin inclusion compound, panthenol, a solution containing the umbilical cord mesenchymal stem cell exosomes, water and normal saline, the concentration of the sodium hyaluronate is 0.2 to 0.6 mg / mL; the concentration of the L-ascorbyl palmitate / hydroxypropyl-beta-cyclodextrin inclusion compound ranges from 0.1 mg / mL to 0.4 mg / mL; the concentration of the panthenol is 0.2 to 1.0 mg / mL; the concentration of the umbilical cord mesenchymal stem cell exosome is 0.2 * 10 < 10 >-0.6 * 10 < 10 > parts / mL. The eye drops have good effects on treating xerophthalmia and repairing corneal epithelium injury.

The invention belongs to the technical field of medicines, and particularly relates to application of IR808 in preparation of a medicine for treating eye bacterial infection diseases. According to the invention, IR808 is taken as a photosensitizer, laser irradiation is combined, and singlet oxygen generated by IR808 is utilized to play an antibacterial role. The developed eye drops, intraocular injections, sustained-release nanoparticles and gel preparations are designed aiming at the eye environment, and have good biocompatibility and stability. The treatment scheme in an animal model proves that pathogens including drug-resistant bacteria can be efficiently killed at low concentration, intraocular tissue damage caused by infection can be effectively relieved, and observable toxicity to intraocular cells and the whole body of an experimental animal is not shown. The invention provides a novel effective method for treating bacterial infection of eyes, especially for solving the drug resistance of antibiotics and improving the treatment safety.

This invention belongs to the field of fungal keratitis treatment technology, and discloses a MoSe2-PEI quantum dot, an antifungal eye drop, its preparation method, and its application. The MoSe2-PEI quantum dot is a PEI-modified MoSe2 quantum dot. Preparation steps: (1) Prepare lithium-modified MoSe2 using lithium intercalation-assisted liquid phase exfoliation technology; (2) Disperse the lithium-modified MoSe2 in water by ultrasonication, centrifuge, collect the supernatant, and ultrafilter to obtain an aqueous solution of MoSe2 quantum dots; (3) Add PEI to the aqueous solution of MoSe2 quantum dots under stirring conditions, then sonicate, stir, and finally centrifuge and ultrafilter sequentially to obtain an aqueous solution of MoSe2-PEI quantum dots. An application of the MoSe2-PEI quantum dot in the preparation of a drug for treating fungal keratitis. The MoSe2-PEI quantum dot of this invention can effectively kill the main pathogens causing fungal keratitis.

The invention discloses a nano-robot based on tear driving, a preparation method of the nano-robot and application of the nano-robot in eye drops. The preparation method comprises the following steps: step 1, loading ophthalmic disease treatment drugs such as amphotericin B, voriconazole and natamycin into nano-particles such as polylactic acid-glycolic acid copolymer, chitosan and sodium alginate; 2, coupling urease on the surfaces of the nano-particles to obtain a nano-robot with autonomous movement ability; step 3, performing morphology characterization on the obtained nanometer robot driven by the tear liquid; and step 4, dispersing the prepared tear-driven nano-robot in a buffer solution to prepare the eye drops. The tear-driven nano-robot can utilize urea in tears as fuel to generate cluster motion on the cornea surface, so that the retention time is remarkably prolonged, the drug retention amount is increased, and the treatment effect is improved. The nano-robot eye drops based on tear driving have biocompatibility and treatment safety, and have wide application prospects in the field of ophthalmic local administration.

The application provides a traditional Chinese medicine preparation for treating dry eye, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine preparation comprises the following components in parts by weight: 8-12 parts of chrysanthemum, 8-12 parts of cassia seed, and 8-12 parts of Coptis chinensis / Scutellaria baicalensis. The compatibility and synergistic effect of chrysanthemum, cassia seed and Coptis chinensis / Scutellaria baicalensis in the traditional Chinese medicine preparation, and the drug administration mode of atomization fumigation can make the drug directly act on the ocular surface, improve the local drug concentration, compared with the existing method of simply using sodium hyaluronate eye drops, the preparation can effectively improve the ocular surface inflammation, improve the tear film stability, and fundamentally relieve the core symptoms such as dryness and fatigue of dry eye.

The invention belongs to the field of ophthalmic polypeptides and drugs thereof, and provides an ophthalmic fusion polypeptide with a xerophthalmia relieving effect and an antibacterial effect at the same time, and an ophthalmic preparation containing the polypeptide. The ophthalmic fusion polypeptide provided by the invention has an antibacterial effect, and can reduce or eliminate the use of an antibacterial agent in a preparation, so that the prepared preparation has small irritation and is safer and more effective.